AffiliationDepartment of Surgery, RCSI Smurfitt Building, Beaumont Hospital, Dublin 9,, Ireland.
MetadataShow full item record
CitationSurgeon. 2012 Feb;10(1):53-8. Epub 2011 Sep 9.
JournalThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
AbstractThyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.
- New molecular targeted therapies in thyroid cancer.
- Authors: Milano A, Chiofalo MG, Basile M, Salzano de Luna A, Pezzullo L, Caponigro F
- Issue date: 2006 Sep
- Molecular targeted therapies for patients with refractory thyroid cancer.
- Authors: Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M
- Issue date: 2010 Aug
- Update on thyroid cancer treatment.
- Authors: Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V
- Issue date: 2012 Oct
- [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
- Authors: Zafon C, Obiols G
- Issue date: 2009 Apr
- Target therapies for radioiodine refractory advanced thyroid tumors.
- Authors: Schlumberger M
- Issue date: 2012